Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and SCAN domain-containing protein 5B (ZSCAN5B) is a transcription factor characterized by both a C2H2 zinc finger domain—responsible for sequence-specific DNA binding—and a SCAN domain that mediates protein-protein interactions and dimerization with other SCAN domain proteins[3][4][5]. ZSCAN5B is actively expressed in rapidly dividing cells and its expression is cell-cycle regulated, with a marked peak at mitosis[1]. It preferentially binds to RNA polymerase III transcription units, such as tDNA loci, and can also modulate expression of neighboring RNA polymerase II genes through these binding events[1]. ZSCAN5B is implicated in zygotic genome activation (ZGA): it is expressed during early embryogenesis and promotes genome stability, with loss of function leading to increased chromosomal instability and tumorigenesis in stem cell models[2]. There is currently no evidence that ZSCAN5B is a therapeutic target, nor are there documented small molecule drugs that modulate its activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and SCAN domain-containing protein 5B (ZSCAN5B).